Providence researchers head to Chicago for leading cancer conference

Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, are helping shape the future of cancer care at the 2026 ASCO Annual Meeting in Chicago. 

This premier event brings together leading oncologists, researchers and health care professionals, who share breakthroughs in cancer immunotherapy, emerging treatments and clinical best practices, including AI platforms to accelerate discovery and personalized care. 

Find out which Providence experts are contributing to the 2026 annual meeting and get a glimpse into the studies driving the next wave of cancer research. 

Rapid Oral Abstract Sessions

Genitourinary Cancer—Prostate, Testicular, and Penile

Abstract 5018: Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201

Authors: David Page, et al.

Oral Abstract Sessions

Melanoma/Skin Cancers 

Abstract 9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.

Authors: Matthew Taylor, et al.

Developmental Therapeutics—Immunotherapy

Abstract 2506: Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.

Authors: Rom S. Leidner, et al.

Poster Sessions

Head and Neck Cancer

Abstract 6028: Efficacy and safety of pralsetinib in advanced or metastatic RET altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.

Authors: Matthew Taylor, et al.

Developmental Therapeutics—Immunotherapy

Abstract TPS2670: A first-in-human phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of the novel fas ligand (FasL) inhibitor M3T01 in adults with advanced solid tumors

Authors: Rom S. Leidner, Prakash Ambady, Christopher Darus, William Redmond, Bernard A. Fox, Matthew Taylor, et al.

Breast Cancer 

Abstract 621: Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy.

Authors: David B. Page, et al.

Abstract 623: Event-free survival from the randomized phase 2 neoHIP trial evaluating neoadjuvant taxane, HER2-targeted therapy, +/- pembrolizumab in early-stage HER2-positive breast cancer

Authors: Alison Conlin, Sasha Stanton, Kelly Perlewitz, David B. Page, et al. 

Abstract 1072: A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant selective PI3Kα inhibitor (PI3Kαi), in PIK3CA-mutant advanced solid tumors: Updated results from PIKALO-1.

Authors: David B. Page, et al.

Developmental Therapeutics—Immunotherapy

Abstract 2593: Quality of life in cancer patients treated with anchored interleukin-12 (IL-12) immunotherapy: Results from a first-in-human phase 1 trial of tolododekin alfa (ANK-101)

Authors: Brendan Curti, et al.

Genitourinary Cancer—Kidney and Bladder

Abstract 4534: A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic renal cell carcinoma

Authors: Brendan Curti, et al.

Abstract 4535: Combining HC-7366 with belzutifan in patients with renal cell 

Authors: Brendan Curti, et al.

Central Nervous System Tumors

Abstract 2042: Initial analysis of adoptive neoantigen-specific T-cell immunotherapy for MGMT-unmethylated glioblastoma (TVI-AST-008): Signals amid control arm attrition.

Authors: Prakash Ambady, et al.

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Abstract TPS3155: A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of TAK-188, a novel antibody-drug conjugate (ADC) targeting CCR8+ regulatory T cells, in adult patients with locally advanced or metastatic solid tumors

Authors: Rachel E. Sanborn, et al.

Abstract e15512: Real-world evaluation of a deep learning–based serial CT imaging biomarker with variable thoracic and abdominopelvic coverage in metastatic colorectal and kidney cancers

Authors: R. Bryan Bell, Brendan Curti, et al.

Abstract e15184: Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid

Authors: Rachel E. Sanborn, et al.

Abstract 20510: PRTH-101: An investigational treatment for thoracic solid tumors targeting discoidin domain receptor (DDR1) and the tumor microenvironment (TME)

Author: Rachel E. Sanborn, et al.

Earle A. Chiles Research Institute and Providence Cancer Institute 

Providence Cancer Institute is a leading provider of cancer care in Oregon and a global leader in immuno-oncology. Through its research division, the Earle A. Chiles Research Institute, patients have access to state-of-the-art genomic sequencing, adoptive cellular therapies and a robust clinical research portfolio comprising early phase, investigator-initiated, cooperative group and industry-sponsored trials. Learn more about research at Earle A. Chiles Research Institute. 

Related news 

Adoptive cell therapy: Phase III study open for people with advanced melanoma

New guidelines for treating head and neck cancer could be a game changer

Providence receives esteemed NIH grant for ‘paradigm shift’ in head and neck cancer treatments